Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Chronic Inflammation: Introduction

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...

Cytomegalovirus Disease

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Hypersensitivity Reactions: Immune-Complex Reactions

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating the Use of Anxiety Patient-Reported Outcome Measures (PROMs) in Dementia Clinical Trials: A Systematic Review.

Health expectations : an international journal of public participation in health care and health policy·2026

Same author

Quality of Care in Inflammatory Bowel Disease through Patients' Eyes: Validation of the Portuguese Version of IQCARO-QoC Questionnaire.

GE Portuguese journal of gastroenterology·2026

Same author

International consensus on airway clearance techniques for patients hospitalised with acute exacerbations of COPD: a European Delphi study.

ERJ open research·2026

Same author

The CoughRetrain Program: Restoring Control Through a Non-pharmacological Intervention.

Lung·2026

Same author

Moving Beyond Responders: A Post Hoc Analysis Identifying Criteria for Chronic Cough Control.

Chest·2026

Same author

Bovine Ocular Squamous Cell Carcinoma-A Descriptive Epidemiological Survey in the Azores, Portugal.

Veterinary sciences·2026

Search research articles

Related Experiment Video

Updated: May 21, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Interferon-induced sarcoidosis.

Cláudia Cardoso¹, Ricardo Freire, Ana Alves

¹Department of Gastroenterology, Centro Hospitalar de Setúbal, Setúbal, Portugal. claudiamarcal@gmail.com

BMJ Case Reports

|June 15, 2012

Summary

This summary is machine-generated.

Sarcoidosis is a rare side effect of interferon therapy. This case study shows a patient who developed systemic sarcoidosis with skin lesions during pegylated interferon and ribavirin treatment, which resolved after stopping therapy.

More Related Videos

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: May 21, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

Immunology
Dermatology
Pulmonology

Background:

Interferon therapy, particularly with pegylated interferon and ribavirin, is used for certain chronic conditions.
Sarcoidosis is an inflammatory condition characterized by granuloma formation, with rare documented cases as a side effect of interferon treatment.

Observation:

A 43-year-old male patient developed skin lesions during treatment with pegylated interferon and ribavirin.
These skin lesions were the only clinical sign of systemic sarcoidosis.
The patient also had asymptomatic bilateral hilar lymphadenopathy and pulmonary nodules on imaging.

Findings:

Systemic sarcoidosis developed as an adverse event in a patient undergoing interferon-based therapy.
The presentation was primarily dermatological, accompanied by subclinical pulmonary involvement.
Cessation of pegylated interferon and ribavirin led to significant clinical and radiological improvement.

Implications:

This case highlights the importance of considering sarcoidosis as a potential rare side effect of interferon therapy.
Dermatologists and pulmonologists should be aware of this association when patients present with relevant symptoms during or after such treatments.
Early recognition and discontinuation of the offending agent can lead to favorable outcomes in interferon-induced sarcoidosis.